Developmental Research Program

项目总结(发展研究计划) MD安德森前列腺癌中心发展研究计划(DRP)的目标 癌症孢子将资助翻译前列腺癌研究中有前途的研究。该片由Dr。 蒂莫西·C·汤普森，克里斯托弗·J·洛戈蒂斯博士联合执导。就像我们现在的孢子一样，DRP 在这一更新中，将强调对能够产生临床可检验的翻译研究的支持 有助于降低前列腺癌发病率和死亡率和/或提高患者生活质量的假设 前列腺癌患者。前列腺癌孢子管理核心已经建立了一个广泛的 努力征集潜在的DRP项目。创新意向书不超过2页 翻译研究邀请了MD安德森和外部机构以及孢子和非孢子 调查人员，包括孢子职业发展计划的参与者。这些应用程序将是 由项目主任和联席主任(兼任孢子首席调查员和 联合首席调查员)根据客观标准。选定申请的调查人员将被要求 以美国国立卫生研究院R01为蓝本，准备一份5页的建议书。在适当的情况下， 行政核心主任和工作人员将协助调查人员提交建议制定翻译 具体的目标和研究计划，因为这些调查人员中的许多人不具备这些领域的专业知识。这个 过程构成了一项重大的教育活动，并将进一步刺激创新能力的发展 翻译研究概念。这些提案将由前列腺癌进行审查并确定优先顺序 孢子负责人(首席调查员、项目联合负责人、项目主管和核心主管)。这个 项目将获得为期一年的资助，并将在已建立的基础上再续签一年 标准。发展研究项目将由项目主任/合作伙伴进行临时和年度评估 董事、孢子领袖、执行委员会和内部/外部联合咨询委员会。《DRP》 建立了终止不符合我们继续执行标准的项目的机制； 然而，到目前为止，还没有必要在DRP中使用这一机制。 在目前的前列腺癌孢子项目中资助了九个发展项目。调查人员收到DRP 格兰特在2009-2014年间撰写了29本与其赠款支持的研究有关的出版物，并 颁发了19笔外部同行评审赠款。重要的是，两名DRP获奖者是重大项目的调查人员 前列腺癌孢子更新应用：林秀华博士(共同领导，项目2)和Padmanee Sharma(联合领导，项目1)，强调DRP在确定项目和调查人员方面的重要性 具有潜在的翻译研究价值。

PROJECT SUMMARY (Developmental Research Program) The goal of the Developmental Research Program (DRP) of the MD Anderson Cancer Center Prostate Cancer SPORE is to fund promising studies in translational prostate cancer research. It is directed by Dr. Timothy C. Thompson and co-directed by Dr. Christopher J. Logothetis. As with our current SPORE, the DRP in this renewal will emphasize the support of translational research studies that can generate clinically testable hypotheses to help reduce the incidence and mortality of prostate cancer and/or improve the quality of life of prostate cancer patients. The Prostate Cancer SPORE Administrative Core has established a broad-based effort for solicitation of potential DRP projects. Letters of intent of no more than 2 pages for innovative translational research are invited from MD Anderson and outside institutions and SPORE and non-SPORE investigators, including participants in the SPORE Career Enhancement Program. These applications will be screened by the program Director and co-Director (who also serve as the SPORE Principal investigator and co-Principal Investigator) according to objective criteria. Investigators of selected applications will be asked to prepare a 5-page proposal modeled after a National Institutes of Health R01. As appropriate, the Administrative Core Directors and staff will assist investigators submitting proposals formulate translational specific aims and research plans, as many of these investigators will not have expertise in these areas. The process constitutes a major educational activity and will further stimulate the development of innovative translational research concepts. The proposals will be reviewed and prioritized by the Prostate Cancer SPORE Leaders (Principal Investigators, Project co-Leaders, Program Directors, and Core Directors). The projects will be funded for 1 year and will be renewable for an additional year on the basis of established criteria. Developmental Research projects will be evaluated ad hoc and annually by the program Director/co- Director, SPORE Leaders, Executive Committee, and combined Internal/External Advisory Boards. The DRP has established a mechanism for termination of projects that do not meet our criteria for continuation; however, it has not been necessary to utilize this mechanism in the DRP to date. Nine developmental projects were funded in the current Prostate Cancer SPORE. Investigators receiving DRP grants wrote 29 publications related to the research supported by their grants during 2009-2014 and were awarded 19 external peer-reviewed grants. Importantly, 2 DRP awardees are investigators for major projects in the Prostate Cancer SPORE renewal application: Drs. Sue-Hwa Lin (co-Leader, Project 2) and Padmanee Sharma (co-Leader, Project 1), highlighting the importance of the DRP in identifying projects and investigators with potential value for translational research.